Home page > >
Home page > Therapeutic areas > Respiratory


We often consider our breathing and respiratory health to be something granted. However, the lung is a vital organ vulnerable to infection and injury. These alterations prevent him from working properly and this has a direct impact on the quality of life of people and those around him [1]  

These are some of the limitations suffered by people living with a chronic respiratory disease. We are talking about asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. These diseases are characterized, among other things, by a reduction in respiratory flow. Hence, experts point out that they constitute a major public health problem worldwide.

[1] GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1459–1544

Respiratory diseases are the main causes of death and disability in the world. According to WHO (2004) estimates, there are some 235 million people with asthma and 64 million with chronic obstructive pulmonary disease (COPD) [1].  

In Spain, respiratory diseases rank third among the deadliest ailments. According to data from the National Statistics Institute (INE), in 2016 there were 46,812 deaths from lung diseases, which represents 11.4% of the total deaths registered annually in the Spanish geography.  

[1] World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases. A comprehensive approach. Geneva, WHO, 2007. Available from: http://www.who.int/gard/publications/GARD_Manual/en/

Chiesi's approach
At Chiesi we are aware that society needs companies that have leading teams in research and development of medicines and services capable of adapting to technological and demographic transformations and, in this way, provide the population with effective solutions to those pathologies that affect its quality and life expectancy.

As a result of this commitment, Chiesi has presented therapeutic advances in the treatment and control of asthma and COPD. It has also focused on those diseases with the lowest prevalence, such as cystic fibrosis, considered the rare disease with the highest prevalence.

Beyond the medicine...

In recent years, at Chiesi we go further in offering therapeutic solutions, we provide tools and services to help patients improve the management of their pathology or facilitate work of health professionals. In addition, Chiesi is committed to supporting scientific training through scientific meetings in order to be an exchange of knowledge between the medical community. NeumoChiesi, Espacio Asma or BronChiCare are examples of these meetings.

Apps and Respiratory Websites